RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)
October 5th 2022Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
Read More